South Korean regulator approves trophon® EPR Nanosonics Limited (ASX: NAN) today announced the trophon® EPR has been approved for use in South Korea following receipt of a product licence from the Korean Food and Drug Administration (KFDA). “We are delighted to receive regulatory approval in South Korea, well ahead of schedule. South Korea is a strong and growing market for medical devices. The speed of approval is a testament to the quality of our Regulatory and Product Development teams” Dr Weinberger said. “Expanding into new geographic markets will drive the next phase of market adoption of the trophon® EPR as we continue the goal to see our technology accepted as the global standard of care. We are presently in discussions with potential partners for distribution. These discussions are progressing well and there is strong interest from a number of internationally recognised companies.” As previously announced, Nanosonics has also filed for regulatory approval in Mexico and Japan
NAN Price at posting:
88.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)